Placenta-specific protein 1 (PLAC1) expression is significantly down-regulated in preeclampsia via a hypoxia-mediated mechanism

Eric J. Devor\textsuperscript{a,b}, Donna A. Santillan\textsuperscript{a}, Akshaya Warrier\textsuperscript{a}, Sabrina M. Scroggins\textsuperscript{a}, Mark K. Santillan\textsuperscript{a}

\textsuperscript{a}Department of Obstetrics and Gynecology, University of Iowa Carver College of Medicine, Iowa City, IA, USA

\textsuperscript{b}Holden Comprehensive Cancer Center, University of Iowa Hospitals and Clinics, Iowa City, IA, USA

Abstract

\textbf{Objective:} Examine a mechanism of PLAC1 regulation and its potential role in preeclampsia (PE).

\textbf{Materials and methods:} Placental tissue samples and detailed clinical information were obtained through the University of Iowa Maternal Fetal Tissue Bank (IRB# 200910784) from gestational and maternal age-matched control (n=17) and PE affected pregnancies (n=12). PLAC1 and PLAC1 promoter-specific expression was measured using quantitative polymerase chain reaction (qPCR) and differences were assessed via the standard ΔΔCt method. In addition, the role of hypoxia in PLAC1 transcription was investigated through the exposure of HTR8/SVneo human trophoblast cells to the hypoxia mimic dimethyloxaloylglycine (DMOG).

\textbf{Results:} PLAC1 expression is seen to be 8.9-fold lower in human placentas affected by preeclampsia in comparison with controls (p < .05). Further, this decrease is paralleled by a significantly lower expression of the P2 or proximal PLAC1 promoter (p < .05). Expression of mediator complex subunit 1 (MED1), a known hypoxia-sensitive transcription coactivator and PLAC1 effector, is significantly correlated with PLAC1 expression (r\textsuperscript{2}=0.607, p < .001). These data suggest that PLAC1 expression is significantly down-regulated in preeclampsia at least in part via a MED1 hypoxia-mediated mechanism.

\textbf{Conclusions:} We confirm that PLAC1 transcription is suppressed in the placentae of women affected by preeclampsia. We further demonstrate that this suppression is driven through the P2
or proximal PLAC1 promoter. This demonstration led to the identification of the MED1-TRAP cofactor complex as the hypoxia-sensitive driver.

**Keywords**

Preeclampsia placental dysfunction; placenta-specific protein 1 (PLAC1); mediator complex subunit 1 (MED1); hypoxia; dimethyloxaloylglycine (DMOG)

**Introduction**

Preeclampsia affects up to 8% of pregnancies world-wide leading to 76,000 maternal and 500,000 infant deaths per year [1,2]. Appropriate prediction and therapeutic interventions for preeclampsia have been limited by complicated pathogenesis which may be initiated by the immune system but leads to clear vascular, renal, angiogenic, and oxidative dysfunction. Central to the onset of preeclampsia is placental dysfunction [3]. Assessment of placental function in real-time, using in vivo technologies, such as MRI, is being actively pursued [4–7] but the basic pathogenic processes underlying dysfunction remain unclear.

Placenta-specific protein 1 (PLAC1) is a small (212 amino acid) protein encoded by an intronless gene located at chromosome Xq26, a region containing the hypoxanthine phosphoribosyltransferase 1 (HPRT) gene and known to be linked to placentomegaly and intra-uterine growth restriction (IUGR) [8,9]. Normally, PLAC1 is almost exclusively expressed in trophoblast cells of the placenta where it appears to support the endometrial invasion and placental attachment [10,11]. However, numerous investigators have shown that the PLAC1 gene is switched on in a variety of solid tumors including breast [12] as well as uterus, cervix, and ovaries [13–15]. Following the discovery that there are two distinct PLAC1 promoters, termed P1 (or distal) and P2 (or proximal), it was found that the proximal promoter is responsible for the vast majority of messages in placental tissues while the distal promoter is responsible for the vast majority of message in cancers and fetal tissues [16–19].

PLAC1 expression and its regulation raise the question of its role in other placenta-driven gestational disorders, particularly in preeclampsia. Several studies have reported increased levels of PLAC1 mRNA in peripheral blood of women with preeclampsia [20–23]. To date, however, changes in PLAC1 gene expression in placental tissues of women with preeclampsia have only been reported once [24]. In that study, PLAC1 transcription was shown to be suppressed in severe preeclampsia and that hypoxia plays a role in transcriptional suppression. Here, we present evidence confirming that PLAC1 expression is significantly lower in a mixed ethnicity cohort of women who developed preeclampsia. Moreover, we identify in vitro that PLAC1 transcriptional suppression is driven from the P2, or proximal, promoter mediated through the MED1/TRAP transcription mediator complex in response to hypoxia.

**Subjects and methods**

**Cohort assembly**

Placental tissues from 12 women diagnosed with preeclampsia and from 17 women having had full-term, uncomplicated, spontaneous labor, vaginal deliveries were obtained from the
large Maternal Fetal Tissue Bank (MFTB) maintained by the Department of Obstetrics and Gynecology of the University of Iowa Carver College of Medicine [25]. Placentas are uniformly processed and frozen according to published protocols [25]. All biosamples and clinical data are coded and supplied to the investigators for analysis under IRB# 200910784 and IRB# 201603838. As shown in Table 1, the assembled groups were well-matched for maternal age, race, ethnicity, mode of delivery, presence of chronic hypertension, and diabetes. In addition, birth outcomes were similar with regard to the sex of the fetus and APGAR scores. Expectedly, the gestational age at delivery (37.2 vs. 38.6 years, p = .04) was significantly lower in preeclamptic mothers vs. controls and birth weight (3149 vs. 3645 g, p = .06) correspondingly trended lower in children of preeclamptics. Yet, the average gestational age of delivery for both groups was still in the term period.

RNA purification, qPCR, and analysis

Total cellular RNA was prepared from frozen tissue samples using the mirVana miRNA isolation kit (Life Technologies) according to manufacturers’ instructions. RNA yield and quality were assessed using a NanoDrop 1000 as well as an Agilent Model 21 Bioanalyzer in the Genome Division of the University of Iowa Institute of Human Genetics.

All mRNA expression levels were determined using fixed starting RNA mass (250 ng each sample). RNAs were reverse transcribed with SuperScript III following the manufacturer’s recommendations (Life Technologies). Total PLAC1 as well as P1- (Distal Promoter) and P2- (Proximal Promoter) specific mRNA expression was assessed via SYBR Green qPCR assays using the primers sequences shown in Table 2. Also shown in Table 2 are the primer sequences used to determine both MED1 mRNA expression levels and that of the 18S rRNA endogenous control. Individual mRNA expression levels (Ct) were normalized (ΔCt) using an 18S rRNA message. Fold change was calculated via the conventional expression $2^{-\Delta\Delta Ct}$, where $\Delta\Delta Ct = (\text{Mean } \Delta Ct_{PE}) - (\text{Mean } \Delta Ct_{CTRL})$ and significance was assessed using a standard t-test with unequal variances [26–28].

All qPCR assays were carried out on an Applied Biosystems Model 7900HT Real-Time PCR system in the Genomics Division of the University of Iowa Institute of Human Genetics.

Cell culture and DMOG treatment and analysis

HTR8/SVneo trophoblast cells (ATCC, CRL-3271) were grown under optimal conditions in RPMI-1640 media supplemented with 10% Fetal Bovine Serum (Gibco) and 1% antibiotic (Pen-Strep). Six well plates were seeded with $10^5$ cells per well in 3 ml of fresh RPMI-1640 and grown for 24 h. After incubation, the media was replaced with fresh RPMI-1640 media in which 1 M dimethylxaloylglycine (DMOG, TOCRIS Bioscience) was added to final concentrations of 0.5, 1.0, and 2.0 mM. Cells were then grown for an additional 24 h before harvesting and RNA purification. All cell treatments were done in triplicate with controls composed of HTR8/SVneo cells in unaltered RPMI-1640 media. SYBR Green qPCR assays for PLAC1 and MED1 were carried out on HTR8/SVneo RNAs as described above for placental tissues. Fold change for MED1 and PLAC1 for control vs. DMOG treated cells was calculated as above. The dose-response relationship between DMOG concentration
and Fold Change was evaluated using ANOVA with a Bonferroni corrected \( p = .016 \) for statistical significance.

**Results**

PLAC1 mRNA expression in placental tissues of women with preeclampsia as compared with placental tissues of women experiencing an uncomplicated full-term vaginal delivery is shown in Figure 1. As can be seen, PLAC1 expression in placental tissues of women who developed preeclampsia is 8.9-fold lower than it is among placentas from women who did not develop preeclampsia and this decrease is statistically significant \( (p = .041) \). Further, the relative expression of PLAC1 message attributable to the proximal promoter (P2) is 16.8-fold lower among women who develop preeclampsia \( (p = .043) \) while that attributable to the distal promoter (P1) is 6.9-fold lower \( (p = .012) \). This suggests that the vast majority of the decrease in total PLAC1 message in the placentas of women who develop preeclampsia is due to the decrease in proximal promoter-initiated transcription.

We also investigated potential mechanisms influencing this differential promoter-initiated transcription. Mouillet et al. \[29\] demonstrated that hypoxia regulates the transcription coactivator MED1. One of the known direct clients of MED1 is PLAC1 \[29,30\]. We found that MED1 is under-expressed in the placental tissues of women with preeclampsia by nearly 4-fold \((-3.7\text{-fold})\) compared with the control placental tissues. Moreover, using 18S rRNA normalized MED1 and PLAC1 expression \((\Delta Ct)\) from all 29 placental tissues returned a highly significant correlation (Figure 2, \( r^2 = 0.607; p < .01 \)).

To further examine the relationship between hypoxia, MED1, and PLAC1, HTR8/SVneo human trophoblast cells were exposed to increasing concentrations of dimethyloxalylglycine (DMOG), a hypoxia emulator that activates the hypoxia-inducible factor (HIF) system responsible for molecular oxygen sensing \[31\]. Exposure of HTR8/SVneo cells to increasing DMOG concentrations produced a significant dose-dependent decrease in PLAC1 expression (Figure 3). The HTR8 cells also had a correspondingly significant dose-dependent decrease in the expression of MED1 (Figure 3). The high correlation between normalized MED1 and normalized PLAC1 expression seen in the placental tissues was observed in the HTR8/SVneo cells to an even greater degree \( (r^2 = 0.92, p < .05) \).

**Discussion**

Data presented here support a clear negative relationship between preeclampsia and transcription of placenta-specific protein 1 (PLAC1) in placental tissues. We also show that this decreased expression of PLAC1 is driven by the P2, or proximal, promoter. Further, the mechanism underlying these changes can be explained, at least in part, by a hypoxia-driven mechanism operating through the ME1/TRAP mediator transcription coactivator complex.

Koslowski et al. \[18\] demonstrated that C/EBPβ2 is important in regulating PLAC1 transcription and ChiP-Seq data reported in the UCSC Browser (https://genome.ucsc.edu/) confirms the presence of C/EBPβ binding sites in both PLAC1 promoters. We suggest that the link between C/EBPβ2 and PLAC1 that trans-activates the latter is the mediator complex protein MED1 which has been shown to bind C/EBPβ (Figure 4) \[32\]. Mouillet et
al. [33] propose that hypoxia down-regulates MED1 which, in turn, down-regulates PLAC1 transcription. Thus, our current data, in particular, the highly correlated dose-dependent response of PLAC1 and MED1 to the hypoxia-mimetic DMOG in HTR8/SVneo trophoblast cells, provides substantial initial support for a model in which MED1 binds C/EBPβ and trans-activates PLAC1 expression. Moreover, it is the hypoxia sensitivity of MED1 that is driving PLAC1 down-regulation in preeclampsia. Of course, such a mechanism must be more thoroughly explored both in vitro and in vivo.

Extensive genomics analysis of the PLAC1 gene in twenty-five placental mammals and four marsupial and monotreme species demonstrated that this gene appeared soon after the emergence of placental mammals some 165 million years ago and that it has been under strong purifying selection since its’ emergence [34]. Given the tight genomic control on this gene and because PLAC1 is normally almost exclusively expressed in trophoblast cells of the placenta where it appears to promote endometrial invasion and placental attachment [10,11], the consensus view is that PLAC1 is an essential element in the establishment and maintenance of a healthy placenta [8,17,35]. Thus, clinically, PLAC1 represents a novel potential circulating marker for placental health. PLAC1 mRNA levels in the blood are increased in preeclampsia compared with controls. The reason for this is unclear at present but it has been suggested that apoptotic changes in placental villous trophoblasts could be the source [20,21]. Regardless, we suggest that decreased PLAC1 expression in placental tissues coupled with increased mRNA levels in peripheral blood in preeclampsia is yet another marker of compromised placental health in this disorder.

The association of PLAC1 activation by hypoxia also identifies it as a novel pathway for potential targeting in the therapeutics of preeclampsia. This finding is reinforced by the strengths of our study. We used a prospectively enrolled cohort of samples in which women were enrolled early in the pregnancy without regard to disease status. We did not introduce bias by selecting which women to enroll. Although our cohort came from a relatively homogenous population, added to the report by Wan et al. [24] whose cohort was exclusively Asian, there is sufficient ethnic diversity to generalize the results of both studies. This can serve to apply our findings to all cases of preeclampsia, such as those that occur very early in gestation, and to a larger, more diverse population of women.

Conclusions

Placenta-specific protein 1 (PLAC1) has been linked to a variety of gestational disorders including preeclampsia. Our study strengthens the implication of PLAC1 in the pathogenesis of preeclampsia as well as a mechanistic link to hypoxia through the mediator complex MED1. This knowledge may be useful in determining effective interventions that will ultimately lessen or eliminate preeclampsia.

Acknowledgments

We wish to thank the Department of Obstetrics and Gynecology Women’s Health Tissue Repository (DAS, Director) for the placental tissue samples and the Genomics Division of the University of Iowa Institute of Human Genetics (IIHG), in particular, Mary Boes and Garry Hauser, for their continued assistance. In addition, we wish to thank the Institute for Clinical and Translational Science at the University of Iowa for its continued database management support. The Institute for Clinical and Translational Science at the University of Iowa is supported
by the National Institutes of Health (NIH) Clinical and Translational Science Award (CTSA) program, grant U54TR001356. The CTSA program is led by the NIH’s National Center for Advancing Translational Sciences (NCATS).

Funding

This work was supported by the National Institutes of Health Reproductive Scientist Development Program (K12HD00849 to M.K.S.), grants from the American Heart Association (15SFRN23480000, 15SFRN23730000, 15SFRN23760002, and 15SFRN23860007; to M.K.S., D.A.S., E.J.D.), the University of Iowa Interdisciplinary Immunology Postdoctoral Training Program (S.M.S.), the University of Iowa Department of Obstetrics and Gynecology; the University of Iowa Center for Hypertension Research (to D.A.S., M.K.S.), the Shelly Bridgewater Dreams Foundation (M.K.S.), the Swift Family Foundation (M.K.S.). The Genomics Division of the IIHG is funded, in part, by NIH/NCI grant P30CA086862. This publication’s contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH.

Data availability statement

Data supporting the findings reported in this study are available from EJD upon reasonable request.

References

[1]. Duley L The global impact of pre-eclampsia and eclampsia. Semin Perinatol. 2009;33(3):130–137. [PubMed: 19464502]
[2]. Kuklina EV, Ayala C, Callaghan WM. Hypertensive disorders and severe obstetric morbidity in the United States. Obstetrics and Gynecology. 2009;113(6):1299–1306. [PubMed: 19461426]
[3]. Redman CW, Sargent IL. Immunology of pre-eclampsia. Am J Reprod Immunol. 2010;63(6):534–543. [PubMed: 20331588]
[4]. Frias AE, Grove KL. Obesity: a transgenerational problem linked to nutrition during pregnancy. Semin Reprod Med. 2012;30(6):472–478. [PubMed: 23074005]
[5]. Frias AE, Morgan TK, Evans AE, et al. Maternal high-fat diet disturbs uteroplacental hemodynamics and increases the frequency of stillbirth in a nonhuman primate model of excess nutrition. Endocrinology. 2011;152(6):2456–2464. [PubMed: 21447636]
[6]. Frias AE, Schabel MC, Roberts VH, et al. Using dynamic contrast-enhanced MRI to quantitatively characterize maternal vascular organization in the primate placenta. Magn Reson Med. 2015;73(4):1570–1578. [PubMed: 24753177]
[7]. Zhu MY, Milligan N, Keating S, et al. The hemodynamics of late-onset intrauterine growth restriction by MRI. Am J Obstetr Gynecol. 2016;214(3):367.e1–367.e17.
[8]. Jackman SM, Kong X, Fant ME. PLAC1 (placenta-specific 1) is essential for normal placental and embryonic development. Mol Reprod Dev. 2012;79(8):564–572. [PubMed: 22729990]
[9]. Sun D, Wu H, Ping Z, et al. PLAC1 regulates the occurrence of fetal growth restriction by inhibiting the apoptosis of trophoblast cells. Ann Clin Lab Sci. 2021;51:182–189. [PubMed: 33941557]
[10]. Cocchia M, Huber R, Pantano S, et al. PLAC1, an Xq26 gene with placenta-specific expression. Genomics. 2000;68(3):305–312. [PubMed: 10995572]
[11]. Fant M, Barerra-Saldana H, Dubinsky W, et al. The PLAC1 protein localizes to membranous compartments in the apical region of the syncytiotrophoblast. Mol Reprod Dev. 2007;74(7):922–929. [PubMed: 17186554]
[12]. Koslowski M, Sahin U, Mitnacht-Kraus R, et al. A placenta-specific gene ectopically activated in many human cancers is essentially involved in malignant cell processes. Cancer Res. 2007;67(19):9528–9534. [PubMed: 17909063]
[13]. Devor EJ, Leslie KK. The oncoplacental gene placenta-specific protein 1 is highly expressed in endometrial tumors and cell lines. Obstet Gynecol Int. 2013;2013:807849.
[14]. Devor EJ, Reyes HD, Santillan DA, et al. Placentaspecific protein 1: a potential key to many oncofetalplacental OB/GYN research questions. Obstet Gynecol Int. 2014;2014:678984.
[15]. Devor EJ, Reyes HD, Gonzalez-Bosquet J, et al. Placenta-specific protein 1 expression in human papillomavirus 16/18-positive cervical cancers is associated with tumor histology. Int J Gynecol Cancer. 2017;27(4):784–790. [PubMed: 28375929]
[16]. Chen Y, Moradin A, Schlessinger D, et al. RXRa and LXR activate two promoters in placenta-and tumor-specific expression of PLAC1. Placenta. 2011;32(11): 877–884. [PubMed: 21937108]

[17]. Devor EJ. Placenta-specific protein 1 (PLAC1) is a unique onco-fetal-placental protein and an underappreciated therapeutic target in cancer. Integr Cancer Sci Ther. 2016;3:479–483.

[18]. Koslowski M, Tureci O, Biesterfeld S, et al. Selective activation of trophoblast-specific PLAC1 in breast cancer by CCAAT/enhancer-binding protein beta (C/EBPbeta) isoform 2. J Biol Chem. 2009;284(42): 28607–28615.

[19]. Wagner M, Koslowski M, Paret C, et al. NCOA3 is a selective co-activator of estrogen receptor a-mediated transactivation of PLAC1 in MCF-7 breast cancer cells. BMC Cancer. 2013;13:570. [PubMed: 24304549]

[20]. Kodama M, Miyoshi H, Fujito N, et al. Plasma mRNA concentrations of placenta-specific 1 (PLAC1) and pregnancy associated plasma protein A (PAPP-A) are higher in early-onset than late-onset pre-eclampsia. J Obstet Gynaecol Res. 2011;37(4):313–318.

[21]. Kong X, Jackman SM, Fant ME. PLAC1 (placenta-specific 1) is widely expressed during fetal development and is associated with a lethal form of hydrocephalus. Birth Defects Res A Clin Mol Teratol. 2013;97:571–577. [PubMed: 24014101]

[22]. Purwosunu Y, Sekizawa A, Farina A, et al. Cell-free mRNA concentrations of CRH, PLAC1, and selectin-P are increased in the plasma of pregnant women with preeclampsia. Prenat Diagn. 2007;27(8):772–777. [PubMed: 17554801]

[23]. Zanello M, Sekizawa A, Purwosunu Y, et al. Circulating mRNA for the PLAC1 gene as a second trimester marker (14–18 weeks’ gestation) in the screening for late preeclampsia. Fetal Diagn Ther. 2014;36(3): 196–201. [PubMed: 25138310]

[24]. Wan L, Sun D, Xie J, et al. Declined placental PLAC1 expression is involved in preeclampsia. Medicine. 2019;98(44):e17676.

[25]. Santillan MK, Leslie KK, Hamilton WS, et al. Collection of a lifetime: a practical approach to developing a longitudinal collection of women’s healthcare biological samples. Eur J Obstet Gynecol Reprod Biol. 2014;179:94–99. [PubMed: 24965987]

[26]. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(Delta Delta C(T)) Method. Methods. 2001; 25(4):402–408. [PubMed: 11846609]

[27]. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008; 3(6):1101–1108. [PubMed: 18546601]

[28]. Snedecor GW, Cochran WG. Statistical methods. 7th ed. Ames, IA: Iowa State University Press; 1980.

[29]. Mouillet JF, Chu T, Nelson DM, et al. MiR-205 silences MED1 in hypoxic primary human trophoblasts. FASEB J. 2010;24(6):2030–2039. [PubMed: 20065103]

[30]. Doridot L, Miralles F, Barbaux S, et al. Trophoblasts, invasion, and microRNA. Front Genet. 2013;4:248. [PubMed: 24312123]

[31]. Elvidge GP, Glenny L, Appelhoff RJ, et al. Concordant regulation of gene expression by hypoxia and 2-oxoglutarate-dependent dioxygenase inhibition: the role of HIF-1alpha, HIF-2alpha, and other pathways. J Biol Chem. 2006;281(22):15215–15226.

[32]. Li H, Gade P, Nallar SC, et al. The Med1 subunit of transcriptional mediator plays a central role in regulating CCAAT/enhancer-binding protein-beta-driven transcription in response to interferon-gamma. J Biol Chem. 2008;283(19):13077–13086.

[33]. Mouillet JF, Chu T, Hubel CA, et al. The levels of hypoxia-regulated microRNAs in plasma of pregnant women with fetal growth restriction. Placenta. 2010; 31(9):781–784. [PubMed: 20667590]

[34]. Devor EJ. Placenta-specific protein 1 is conserved throughout the placenta under purifying selection. Scientific World Journal. 2014;2014:537356.

[35]. Fant ME, Fuentes J, Kong X, et al. The nexus of prematurity, birth defects, and intrauterine growth restriction: a role for plac1-regulated pathways. Front Pediatr. 2014;2:8.

[36]. Devor EJ, Gonzalez-Bosquet J, Warrier A, et al. p53 mutation status is a primary determinant of placenta-specific protein 1 expression in serous ovarian cancers. Int J Oncol. 2017;50(5):1721–1728. [PubMed: 28339050]
Figure 1.
Expression of total PLAC1 message in placentas from preeclampsia affected pregnancies as compared with controls. Also shown is the expression of both P1- and P2-specific promoter-driven transcription from the same samples.*p < .05.
Figure 2.
Normalized PLAC1 and MED1 expression in placental tissues is significantly correlated ($r^2 = 0.607$, $p < .001$, $df = 28$).
Figure 3.
Changes in PLAC1 (left) and MED1 (right) expression in HTR8/SVneo trophoblast cells in response to dimethylxaloylglycine (DMOG) exposure. Fold change is presented in relation to untreated cells and statistical significance refers to the dose-response over all three dosing levels.
Figure 4.
A model of PLAC1 expression. Message is transcribed from two separate promoters, P1 and P2. PLAC1 message in cancers is primarily driven by the P1 promoter via the transcription factors RXRα and LXRβ and is regulated, in part, by the p53 tumor suppressor [36]. PLAC1 message in the placenta is primarily driven by the P2 promoter via the transcription factor C/EBPβ which is regulated, in part, by the MED1/TRAP transcription mediator complex.
Table 1.

Clinical features of the patients and controls used in this study.

| Character                  | Controls (n = 17) | Preeclamptic (n = 12) | p-Value |
|----------------------------|------------------|-----------------------|---------|
| Race/ethnicity             |                  |                       |         |
| White                      | 13 (76.5%)       | 11 (91.6%)            | .50 *   |
| Black                      | 1 (5.9%)         | 1 (8.3%)              |         |
| Asian                      | 2 (11.8%)        |                       |         |
| Native American            | 1 (5.9%)         |                       |         |
| Maternal age at delivery   | 28.9 years       | 32.6 years            | .11 #   |
| Gestational age at delivery| 38.6 weeks       | 37.2 weeks            | .04 #   |
| Mode of delivery           |                  |                       |         |
| Vaginal                    | (47.1%)          | 5 (41.7%)             | .90 *   |
| Cesarean                   | (52.9%)          | 7 (58.3%)             |         |
| Fetal gender               |                  |                       |         |
| Female                     | 11 (64.7%)       | 6 (50.0%)             | .71 *   |
| Male                       | 6 (35.3%)        | 6 (50.0%)             |         |
| Maternal chronic hypertension| 2 (11.8%)       | 3 (25.0%)             | .62 *   |
| Diabetes                   |                  |                       |         |
| Type I                     | 1 (5.9%)         | 1 (5.9%)              | .67 *   |
| Type II                    | 1 (5.9%)         |                       |         |
| Gestational                | 2 (11.8%)        | 2 (16.7%)             |         |
| Fetal birthweight (g)      | 3645 ± 587       | 3149 ± 713            | .06 #   |
| APGAR (median)             |                  |                       |         |
| 1 min                      | 8                | 9                     | .523 g  |
| 5 min                      | 8                | 9                     | .523 g  |

All clinical information is logged into the Maternal–Fetal Tissue Bank (MFTB) and linked via de-identified tags in compliance with University of Iowa IRB regulations.

* Fisher’s exact test.
# Student’s t-test.
¶ Mann–Whitney Rank Sum Test.
Table 2.

Primer sequences were used in the SYBR Green qPCR assays reported in this study.

| Target  | Amplicon | Sequence                      |
|---------|----------|-------------------------------|
| Total PLAC1 | 232 bp   | Forward: 5'-CACCAGTGAGCACAAGCCACATT-3'  <br>Reverse: 5'-CCATGAACCAGTGATATGGAG-3' |
| P1-specific | 370 bp  | Forward: 5'-AAACTTACACGAGGAGTCTGTC-3'  <br>Reverse: 5'-CTGTAACCATGAACCAGTCTAAT-3' |
| P2-specific | 361 bp  | Forward: 5'-GTGACTCTCCATGAAGGTAAGG-3'  <br>Reverse: 5'-CCATGAACCAGTGATATGGAG-3' |
| MED1     | 319 bp   | Forward: 5'-CAGACACCAAGTGGCCTATAAC-3'  <br>Reverse: 5'-GTTCAGCTTCTTCTCCGAATA-3' |
| 18S rRNA | 104 bp   | Forward: 5'-AACTTTCATGGTGGAGTCGCG-3'  <br>Reverse: 5'-CTTGGADTGGTGAGCCGTTC-3' |